Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Retained Earnings: 2011-2024

Historic Retained Earnings for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to -$199.8 million.

  • Capricor Therapeutics' Retained Earnings fell 42.54% to -$274.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.7 million, marking a year-over-year decrease of 42.54%. This contributed to the annual value of -$199.8 million for FY2024, which is 25.39% down from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Retained Earnings is -$199.8 million, which was down 25.39% from -$159.4 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Retained Earnings ranged from a high of -$88.0 million in FY2020 and a low of -$199.8 million during FY2024.
  • In the last 3 years, Capricor Therapeutics' Retained Earnings had a median value of -$159.4 million in 2023 and averaged -$165.4 million.
  • Data for Capricor Therapeutics' Retained Earnings shows a maximum YoY declined of 26.85% (in 2022) over the last 5 years.
  • Over the past 5 years, Capricor Therapeutics' Retained Earnings (Yearly) stood at -$88.0 million in 2020, then declined by 22.74% to -$108.1 million in 2021, then decreased by 26.85% to -$137.1 million in 2022, then fell by 16.26% to -$159.4 million in 2023, then declined by 25.39% to -$199.8 million in 2024.